Hospira Challenges Amgen's $70M Biosimilar Verdict
Hospira Inc. on Wednesday attacked a $70 million jury verdict for patent infringement related to its proposed biosimilar of Amgen Inc.'s anemia drug Epogen, telling a Delaware federal judge that it...To view the full article, register now.
Already a subscriber? Click here to view full article